These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 31142599)
1. A Deficit of CEACAM-1-Expressing T Lymphocytes Supports Inflammation in Primary Progressive Multiple Sclerosis. Piancone F; Saresella M; Marventano I; La Rosa F; Caputo D; Mendozzi L; Rovaris M; Clerici M J Immunol; 2019 Jul; 203(1):76-83. PubMed ID: 31142599 [TBL] [Abstract][Full Text] [Related]
2. A role for the TIM-3/GAL-9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis. Saresella M; Piancone F; Marventano I; La Rosa F; Tortorella P; Caputo D; Rovaris M; Clerici M FASEB J; 2014 Nov; 28(11):5000-9. PubMed ID: 25091272 [TBL] [Abstract][Full Text] [Related]
4. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion. Rangachari M; Zhu C; Sakuishi K; Xiao S; Karman J; Chen A; Angin M; Wakeham A; Greenfield EA; Sobel RA; Okada H; McKinnon PJ; Mak TW; Addo MM; Anderson AC; Kuchroo VK Nat Med; 2012 Sep; 18(9):1394-400. PubMed ID: 22863785 [TBL] [Abstract][Full Text] [Related]
5. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Killestein J; Den Drijver BF; Van der Graaff WL; Uitdehaag BM; Polman CH; Van Lier RA Mult Scler; 2001 Jun; 7(3):145-50. PubMed ID: 11475436 [TBL] [Abstract][Full Text] [Related]
6. Human regulatory memory B cells defined by expression of TIM-1 and TIGIT are dysfunctional in multiple sclerosis. Varghese JF; Kaskow BJ; von Glehn F; Case J; Li Z; Julé AM; Berdan E; Ho Sui SJ; Hu Y; Krishnan R; Chitnis T; Kuchroo VK; Weiner HL; Baecher-Allan CM Front Immunol; 2024; 15():1360219. PubMed ID: 38745667 [TBL] [Abstract][Full Text] [Related]
7. Specific alterations in NKG2D Carmena Moratalla A; Carpentier Solorio Y; Lemaître F; Farzam-Kia N; Da Cal S; Guimond JV; Haddad E; Duquette P; Girard JM; Prat A; Larochelle C; Arbour N Mult Scler Relat Disord; 2023 Mar; 71():104542. PubMed ID: 36716577 [TBL] [Abstract][Full Text] [Related]
8. Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Harp CT; Ireland S; Davis LS; Remington G; Cassidy B; Cravens PD; Stuve O; Lovett-Racke AE; Eagar TN; Greenberg BM; Racke MK; Cowell LG; Karandikar NJ; Frohman EM; Monson NL Eur J Immunol; 2010 Oct; 40(10):2942-56. PubMed ID: 20812237 [TBL] [Abstract][Full Text] [Related]
9. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. Lassmann H Front Immunol; 2018; 9():3116. PubMed ID: 30687321 [TBL] [Abstract][Full Text] [Related]
10. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. Romme Christensen J; Börnsen L; Ratzer R; Piehl F; Khademi M; Olsson T; Sørensen PS; Sellebjerg F PLoS One; 2013; 8(3):e57820. PubMed ID: 23469245 [TBL] [Abstract][Full Text] [Related]
11. Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients. Zhang Y; Cai P; Li L; Shi L; Chang P; Liang T; Yang Q; Liu Y; Wang L; Hu L Int Immunopharmacol; 2017 Feb; 43():210-218. PubMed ID: 28038383 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity. Hellings N; Gelin G; Medaer R; Bruckers L; Palmers Y; Raus J; Stinissen P J Neuroimmunol; 2002 May; 126(1-2):143-60. PubMed ID: 12020966 [TBL] [Abstract][Full Text] [Related]
13. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. Zang YC; Li S; Rivera VM; Hong J; Robinson RR; Breitbach WT; Killian J; Zhang JZ J Immunol; 2004 Apr; 172(8):5120-7. PubMed ID: 15067096 [TBL] [Abstract][Full Text] [Related]
14. IL-7-enhanced T-cell response to myelin proteins in multiple sclerosis. Traggiai E; Biagioli T; Rosati E; Ballerini C; Mazzanti B; Ben Nun A; Massacesi L; Vergelli M J Neuroimmunol; 2001 Dec; 121(1-2):111-9. PubMed ID: 11730947 [TBL] [Abstract][Full Text] [Related]
15. Elevated Galectin-9 Suppresses Th1 Effector Function and Induces Apoptosis of Activated CD4 Yang S; Wang J; Chen F; Liu G; Weng Z; Chen J Inflammation; 2017 Jun; 40(3):1062-1071. PubMed ID: 28393295 [TBL] [Abstract][Full Text] [Related]
16. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Jilek S; Schluep M; Meylan P; Vingerhoets F; Guignard L; Monney A; Kleeberg J; Le Goff G; Pantaleo G; Du Pasquier RA Brain; 2008 Jul; 131(Pt 7):1712-21. PubMed ID: 18550621 [TBL] [Abstract][Full Text] [Related]
17. Circulating CD8+CD56-perforin+ T cells are increased in multiple sclerosis patients. Giovanni F; Domenico P; Alessandro M; Raffaele I; Viviana N; Katia PA; Paola BA J Neuroimmunol; 2011 Dec; 240-241():137-41. PubMed ID: 22001684 [TBL] [Abstract][Full Text] [Related]
19. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis. Zafranskaya M; Oschmann P; Engel R; Weishaupt A; van Noort JM; Jomaa H; Eberl M Immunology; 2007 May; 121(1):29-39. PubMed ID: 17239199 [TBL] [Abstract][Full Text] [Related]
20. Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients. Skrzipek S; Vogelgesang A; Bröker BM; Dressel A Mult Scler; 2012 May; 18(5):674-8. PubMed ID: 22025329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]